Ozempic Cost Without Insurance 2026

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3-month and 6-month plans · cancel anytime

Ozempic cost without insurance: at a glance

Prices reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, and your insurer before deciding. For a broader comparison of GLP-1 telehealth pricing, see the Nouri GLP-1 telehealth pricing dataset (HuggingFace, June 2026).

What does Ozempic actually cost without insurance?

The headline you'll see most often is the list price: approximately $997/month for a one-month supply of Ozempic. That number, published by Novo Nordisk, is the starting point for insurer negotiations and pharmacy billing — but it is rarely the price an uninsured patient pays.

Novo Nordisk's NovoCare self-pay program offers a substantially lower out-of-pocket option. As of June 2026, that program prices Ozempic at roughly $349/month, with an introductory price of approximately $199/month for the first two months. These figures are subject to change; confirm the current offer directly on NovoCare's website before making a decision.

The gap between list price and self-pay price is not unusual in US drug pricing, where manufacturers often operate parallel access programs alongside the insurer-negotiated supply chain. For Ozempic, the NovoCare self-pay offer exists because the drug's diabetes indication gives Novo Nordisk an incentive to maintain patient access outside insurance — while the branded weight-loss product, Wegovy, has its own access program.

Ozempic cost with insurance

If you have commercial insurance and your plan covers Ozempic for type 2 diabetes, a Novo savings card can reduce your monthly copay to as little as $25/month. That is the most cost-effective route for patients with a qualifying diabetes diagnosis and commercial coverage.

Several important caveats apply:

• Indication matters. Ozempic is covered for type 2 diabetes. Prescribing it for weight loss is off-label; insurers almost universally will not cover that indication.
• Prior authorization is common. Most commercial plans require prior authorization before dispensing Ozempic, even for the diabetes indication. Approval is not guaranteed.
• Medicare and Medicaid are excluded from the Novo savings card. If you are on a government plan, the savings card is not available.
• Plan formularies change. Verify your specific plan's current formulary and cost-sharing before assuming a $25 copay applies to you.

For a detailed walkthrough of how to navigate insurer prior-authorization for GLP-1 medications, see How to get a GLP-1 covered by insurance.

Does insurance cover Ozempic for weight loss?

Generally no. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for improving glycemic control in adults with type 2 diabetes and, at higher doses, for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It does not carry an FDA-approved weight-loss indication.

The semaglutide product approved for chronic weight management is Wegovy (semaglutide 2.4 mg), which has a different approval pathway and its own, narrower set of coverage rules. Even Wegovy coverage remains limited — most commercial plans require documentation of comorbidities and a prior-authorization process. For details, see Does insurance cover Wegovy and Zepbound?

Why does Ozempic cost so much?

Three factors explain the elevated list price:

1. No generic competition. There is no FDA-approved generic semaglutide in the United States. Novo Nordisk holds patents on semaglutide that are expected to run approximately to 2032. Until a generic receives approval, Novo sets the list price without direct competitive pressure from a lower-cost equivalent. (Drugs.com, Generic Ozempic availability, 2026)
2. Structural US drug pricing. Unlike most peer countries, the US does not have a national body that negotiates or caps drug prices before market entry. List prices are set by the manufacturer; the insurer-negotiated "net price" is lower, but that discount does not directly benefit an uninsured buyer.
3. Demand pressure. Ozempic is one of the most-prescribed drugs in the US, partly because prescribers use it off-label for weight loss. High demand with a single-source supply does not create pricing downward pressure.

The Inflation Reduction Act created a mechanism for Medicare to negotiate drug prices starting in 2026 — a CMS program for GLP-1 medications at $50/month for eligible Medicare beneficiaries was announced for launch in July 2026. That does not affect non-Medicare patients, but it represents the first significant statutory intervention on semaglutide pricing in the US.

Is there a generic Ozempic?

No. There is no FDA-approved generic version of Ozempic available in the United States as of mid-2026. Novo Nordisk's patent protection on the semaglutide molecule and its delivery system is expected to remain in force until approximately 2032. Generic manufacturers cannot legally market a bioequivalent product until after patent expiration and FDA approval of an Abbreviated New Drug Application (ANDA).

This is meaningfully different from traditional small-molecule drugs, where generics arrive within a few years of exclusivity expiration. GLP-1 agonists are complex injectable biologics; the technical and regulatory barrier to generic entry is higher.

For a broader breakdown of all GLP-1 pricing options — brand and compounded — see the complete GLP-1 cost guide for 2026.

Ozempic vs. Wegovy: what is the difference in cost and indication?

Ozempic and Wegovy both contain semaglutide, but they are distinct FDA-approved products with different approved indications and doses:

If weight management is the clinical goal and cost is a concern, those are separate clinical and financial decisions that belong in a conversation with a licensed clinician. For more detail, see Wegovy cost without insurance.

What about compounded semaglutide?

During the years when Wegovy and Ozempic faced significant supply shortages, the FDA exercised enforcement discretion that allowed 503A and 503B compounding pharmacies to prepare compounded versions of semaglutide. The FDA removed semaglutide from its shortage list in 2025, which changed the legal landscape for compounding pharmacies. Consult the FDA's human drug compounding guidance for current status.

Where compounded semaglutide is lawfully prescribed and dispensed, it is typically prepared at a 503A compounding pharmacy — a state-licensed facility that fills patient-specific prescriptions. Telehealth programs that offer compounded semaglutide generally work with these pharmacies. Cost for compounded semaglutide via telehealth programs ranges broadly from approximately $99 to $199+ per month, depending on the program structure and what is included.

One variable to examine closely: some programs advertise a low "from" price (e.g., "$99/month") that represents medication only, with a separate monthly membership fee of $49–$79 added on top. Compare all-in, apples-to-apples monthly cost, not the promotional headline number. The Nouri GLP-1 telehealth pricing dataset tracks all-in pricing across providers as of June 2026.

For a full breakdown of the cost and structural differences between compounded and brand GLP-1 medications, see Compounded vs. brand GLP-1 cost.

Can you use FSA or HSA funds for Ozempic?

If Ozempic is prescribed for a qualifying medical condition (such as type 2 diabetes), it is generally an eligible expense under an FSA or HSA because it constitutes a prescription drug under IRC §213(d). However, if prescribed off-label for weight loss without a qualifying diagnosis, eligibility may be less clear-cut and plan-dependent.

Compounded semaglutide prescribed by a licensed clinician may also be eligible for FSA/HSA reimbursement under §213(d), since a lawful prescription makes it a qualifying medical expense — but this is a reimbursement process (submit a receipt), not a direct-card transaction, and eligibility depends on your specific plan. In some cases, a letter of medical necessity from your provider may be required.

Always confirm FSA/HSA eligibility with your plan administrator and, for tax questions, a qualified tax professional. This is general information, not tax or financial advice. For more, see Can you use HSA/FSA for a GLP-1?

Related cost guides

• GLP-1 cost guide 2026 (all options) — the pricing pillar for this cluster
• Semaglutide cost (all forms and providers)
• Wegovy cost without insurance
• Zepbound cost without insurance
• Does insurance cover Wegovy and Zepbound?
• Compounded vs. brand GLP-1 cost
• Comparing GLP-1 costs: every option side by side

Where Nouri fits on cost

Nouri's compounded semaglutide program is priced at $120/month on the 6-month plan ($720 billed every 6 months), $145/month on the 3-month plan ($435 billed every 3 months), or $175/month billed monthly. Compounded tirzepatide is $175/month on the 6-month plan ($1,050), $199/month on the 3-month plan ($597), or $225/month billed monthly. These are all-in prices — no separate membership fee, no per-dose surcharge, no hidden add-ons.

The price includes the compounded GLP-1 medication when prescribed, a personalized nutrition plan, a movement plan, and access to the Nouri Care Team — U.S.-licensed physicians who review your intake and, if appropriate, prescribe. It is available in all 50 states for adults.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Watch for programs advertising "$99/month" that add a $49–$79 monthly membership fee on top. Compare the all-in number. For a transparent side-by-side of how program pricing structures vary across providers, see the Nouri GLP-1 telehealth pricing dataset.

Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, Ozempic, Wegovy, Mounjaro, or Zepbound. Medication is prescribed only if a licensed clinician determines it is appropriate after reviewing your health intake. Not all applicants qualify. Individual results vary.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3-month and 6-month plans · available in all 50 states

Frequently asked questions

How much does Ozempic cost per month without insurance?

As of June 2026, Ozempic's list price is about $997/month. Novo Nordisk's NovoCare self-pay program currently offers it at approximately $349/month, with a roughly $199/month introductory price for the first two months. Verify the current offer directly on NovoCare before deciding — these figures are updated periodically and change without notice.

How much is Ozempic a month?

Without insurance, the effective self-pay price via NovoCare is roughly $349/month (with a ~$199/month intro for the first two months). The list price of ~$997 is rarely what patients actually pay. With commercial insurance covering the diabetes indication, a Novo savings card can bring the copay to as little as $25/month.

Why is Ozempic so expensive?

There is no FDA-approved generic — Novo Nordisk's patents run approximately to 2032. Combined with intense demand and the absence of statutory price controls for brand drugs in the US, list prices remain high. The manufacturer's NovoCare self-pay program (~$349/month) and insurance savings cards (as low as $25/month when covered for diabetes) are the primary mechanisms for reducing cost.

How much is Ozempic with insurance?

If your plan covers Ozempic for type 2 diabetes and you have commercial insurance, a Novo savings card can bring the copay to as little as $25/month. Prior authorization is commonly required. Coverage for off-label weight-loss use is generally not available. Savings cards exclude Medicare and Medicaid.

Does insurance cover Ozempic for weight loss?

Generally no. Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction — not weight loss. Insurers almost universally will not cover an off-label indication. The on-label semaglutide weight-management product is Wegovy, which carries its own (narrower) coverage landscape. For coverage guidance, see How to get a GLP-1 covered by insurance.

Is there a generic Ozempic available?

No. There is no FDA-approved generic Ozempic in the United States as of mid-2026. Patents on semaglutide are expected to run approximately to 2032. Compounded semaglutide is not a generic — it is a patient-specific preparation made by a state-licensed 503A pharmacy, and it is not FDA-approved.

How much is Ozempic with the savings card?

For commercially insured patients whose plan covers Ozempic for type 2 diabetes, the Novo savings card can reduce the copay to as little as $25/month. The card is not available to Medicare or Medicaid patients. Confirm your plan's current formulary and savings-card eligibility before assuming this price applies.

Sources and references

1. Novo Nordisk NovoCare — Ozempic list price and self-pay program (accessed June 2026)
2. FDA — Postmarket drug safety information; GLP-1 receptor agonists
3. FDA — Human drug compounding guidance and enforcement policy
4. NIH/NIDDK — Prescription medications to treat overweight and obesity
5. Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM 2021. — Published research on the semaglutide molecule; not a statement about Nouri's compounded product.
6. CMS — Medicare GLP-1 $50/month access program announcement
7. Drugs.com — Generic Ozempic availability (accessed June 2026)
8. Nouri GLP-1 telehealth pricing dataset (HuggingFace, June 2026) — all-in pricing across GLP-1 telehealth providers

Medically reviewed by Amber Patel, MD. Nouri editorial content is reviewed by licensed clinicians and updated as pricing, guidance, and regulatory status change.

Prices and coverage described here reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for FSA/HSA or tax questions) a qualified tax professional before making any decisions. This content is general health information, not medical, financial, or tax advice, and does not constitute a provider-patient relationship. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, any brand-name drug. Medication is prescribed only if a licensed clinician determines it is clinically appropriate after reviewing an individual's health intake. Not all applicants qualify. Individual results vary.